🔜 #ELCC26 @myesmo.bsky.social
🔥Perioperative treatments for early lung cancer
☑️ #AGA #Adjuvant #Neoadjuvant #Perioperative #Biomarker
🎙️Chair: Dr. Enriqueta Felip, Dr. James Spicer
@oncoalert.bsky.social LARVOL #LCSM
🔜 #ELCC26 @myesmo.bsky.social
🔥Neoadjuvant vs perioperative in stage II NSCLC: Just to keep things confusing
☑️ #Neoadjuvant vs. #Perioperative
🎙️Chair: Dr. Mariano Provencio Pulla
@oncoalert.bsky.social LARVOL #LCSM
#Article in @MedComm_MC
Triple #HER2 Blockade With #Trastuzumab, #Pertuzumab, and #Pyrotinib Versus Dual HER2 Blockade in the #Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Randomized, Phase II Study doi.org/10.1002/mco2...
#ClinicalTrial
A multicenter, open-label, randomized, phase II trial evaluating the efficacy and safety of perioperative #Penpulimab plus #Anlotinib with or without #Neoadjuvant #Chemotherapy, promising efficacy and a manageable safety profile in patients with resectable #NSCLC
#OpenAccess: doi.org/10.1038/s413...
#Neoadjuvant #tislelizumab plus nab‑paclitaxel and #anthracycline‑based #chemotherapy achieved 68.2% pCR and 93.2% ORR in #TNBC, while #multiomics profiling revealed immune pathway enrichment and CDKN1A+CD8 T cells linked to response.
#OpenAccess in #STTT: doi.org/10.1038/s413...
High CD8⁺ #TumorInfiltrating lymphocyte density within #necrotic regions robustly predicts improved event-free survival in #NSCLC after #neoadjuvant #immunochemotherapy, outperforming #radiologic and pathological responses. @upenn.edu
#OpenAccess in #STTT: doi.org/10.1038/s413...
At #SABCS2025, new translational results from the #NSABP B-59/GBG-96- #GeparDouze trial were presented by Carsten Denkert, highlighting how #TIL levels and molecular #TNBC subtypes shape response to #neoadjuvant immune-chemotherapy.
➡️ Full details are available here:
www.gbg.de/news/detail/...
📣 Meet #GBG at #SABCS2025 – Highlights for December 9!
3 high-impact Rapid Fire Presentations featuring new analyses from leading #neoadjuvant and #immunotherapy trials.
All presentation materials will be made available after the conference here: www.gbg.de/news/detail/...
The NATIC trial, evaluating #Neoadjuvant anti-PD-1 #Tislelizumab + #Chemotherapy in treatment-naïve stage IB3/IIA2 LACC patients, showed promising #Antitumor efficacy and a tolerable safety profile. #medsky
#STTT #OpenAccess: doi.org/10.1038/s413...
The NATIC trial, evaluating #Neoadjuvant anti-PD-1 #Tislelizumab + #Chemotherapy in treatment-naïve stage IB3/IIA2 LACC patients, showed promising #Antitumor efficacy and a tolerable safety profile. #medsky
#STTT #OpenAccess: doi.org/10.1038/s413...
#NeoRad study #GBG116: phase III trial investigating whether #preoperative radiotherapy can improve disease-free survival compared to #postoperative #radiotherapy after #neoadjuvant #chemotherapy in patients with high-risk early breast cancer.
👉 More information: www.gbg.de/en/trials/neorad
Join me & MIA multidisciplinary experts at Neoadjuvant Treatment Symposium, to help clinicians navigate the evolving treatment landscape for #melanoma, after recent PBS listing for #neoadjuvant regimens. Mon evening 24 Nov AEDT in person in Sydney, or online. events.humanitix.com/neoadjuvant-...
#GeparPiPPa #GBG105 investigates #neoadjuvant #endocrine therapy in combination with #trastuzumab and #pertuzumab, with or without the #PI3K inhibitor #inavolisib, in patients with HER2-positive, HR-positive, PIK3CA-mutated primary breast cancer.
Learn more about the study www.gbg.de/en/trials/ge...
#Flamingo-01 #GBG111: a global phase III, randomized, placebo-controlled study investigating the GLSI-100 immunotherapy in HLA-A*02-positive and HER2/neu-positive breast cancer patients who remain at high risk of #recurrence after completing both #neoadjuvant and #adjuvant standard therapy.
#PinkOctober: The study reveals that luminal breast tumors can dynamically change under #neoadjuvant #chemotherapy - with aggressive #Luminal B tumors often transitioning into a less aggressive Luminal A type.
Read full publication here: www.cell.com/cancer-cell/...
Phase 2-3 ZSAB-neoGOLP trial of #neoadjuvant GOLP regimen for resectable i#CCA with high-risk features for recurrence. A positive interim analysis, but not a standard regimen. Novel approaches are needed.
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
This study identifies #CD8+ nTILs as a strong predictor of event‑free survival in #NSCLC following #neoadjuvant PD‑1 #immunochemotherapy, outperforming radiologic and pathologic responses regardless of PD‑L1 status or #LymphNodeMetastasis. @upenn.edu
#STTT: doi.org/10.1038/s413...
This study identifies Δ#Ki67 and ΔKi67% as potent #Biomarkers for predicting response to #Anthracycline-based #Neoadjuvant #Chemotherapy in #BreastCancer, providing valuable insights for #Clinical decision-making and personalized #CancerCare. #medsky
Read:
CA209-7AL, a #ClinicalTrial evaluating the efficacy & safety of consolidative #Nivolumab (NIVO) Vs observation following #neoadjuvant NIVO + #chemotherapy & concurrent #Chemoradiotherapy reveals both efficacy & tolerability in stage III #NSCLC.
Read: doi.org/10.1038/s413...
Coming up at #ASTRO25: MSK’s Dr. Nancy Lee will discuss #neoadjuvant and #adjuvant pembrolizumab plus standard of care in resectable locally advanced head and neck squamous cell #carcinoma. @astro-org.bsky.social
Tuesday, 9/30 | 2:30 p.m. PDT
Learn more: bit.ly/4pNSt7K
Novartis' Entresto can help with heart problems caused by the chemotherapy drugs epirubicin and cyclophosphamide.
#cancer #oncology #breastcancer #neoadjuvant #sacubitril #valsartan
www.medscape.com/viewarticle/...
Evaluation of the efficacy & safety of adding #Pyrotinib to a #neoadjuvant regimen of #Trastuzumab & #chemotherapy in HER2-positive #BreastCancer patients showed that pyrotinib elicits a beneficial response. #medsky
#STTT #OpenAccess: doi.org/10.1038/s413...
Enduring materials are available for the #SITC Summit on the Future of #Neoadjuvant #Clinical Trial Design! This summit highlighted recent advances, opportunities & challenges in the field of #neoadjuvant #immunotherapy! View for FREE: sitcancer.org/viewdocument/sitc-summit-on-the-future-of-neoadj
INNOVATE Naples - Paolo Ascierto hosts clinician/researchers discussing #CANCER #NEOADJUVANT #immunotherapy. Favorite meeting for patient-centered novel trials. Discussed optimising immunotherapy across multiple cancers & #melanoma to cure more Grazie tutti!
Latest #MelanomaInsights podcast: Is sentinel node biopsy still recommended in 2025 with the rise of #neoadjuvant immunotherapy? Search “Melanoma Insights” in podcast app or listen here> bit.ly/4kaGnkV (free, clinicians only, login needed). #SNB
Thanks to #NADINA clinical trial, led by MIA with Netherlands colleagues, #neoadjuvant (pre-surgery) use of combination #immunotherapy drugs nivolumab and ipilimumab approved by #PBAC & will be listed on #PBS as treatment for Stage III melanoma. @9news.bsky.social
@gvlongphdmd.bsky.social
Attend the #SITC Summit on the Future of #Neoadjuvant Clinical Trial Design on June 26, 2025 to hear recent advances in clinical trials for resectable #tumors. The Neoadjuvant Clinical Trial Design Working Group is chaired by Patrick Forde, MD. Register: sitcancer.org/neoadjuvant-vs #cancerresearch
NCI blog patient story for trial NCT06223568 #neoadjuvant chemo (cisplatin&docetaxel) & #HPV #immunotherapy (PRGN-2009) for newly diagnosed HPV-positive OPSCC (PI Dr Clint Allen): omission of adjuvant radiotherapy per response to neoadj Tx & surg path risk factors.
ccr.cancer.gov/news/article...
#Neoadjuvant cDC1-based vaccination enhances CD8+ and CD4+ memory T cell responses upon tumor recurrence. cDC1 immunotherapy triggers a CD4+ Trm subset as the key subset increased and associated also to augmented CD8+ T cell cytotoxic response.
#immunosky #cancersky (5/7)
